Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.

11 de noviembre de 2026 actualizado por: Novartis Pharmaceuticals

An Open-label, Single-arm, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients Who Have Completed a Clinical Trial (Parent Study) in the Iptacopan Pediatric Program

The purpose of this single-arm, multicenter, Phase IIIb roll-over extension study is to assess the long-term safety, tolerability, and efficacy of iptacopan in participants with complement mediated diseases.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a Phase IIIb, multicenter, open-label, single-arm roll-over extension study designed to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who, in the opinion of the investigator, continue to derive clinical benefit from treatment. The study will provide post-trial access to iptacopan while continuing to collect long-term safety and efficacy data.

Eligible participants who have completed a pediatric iptacopan parent study will continue to receive open-label iptacopan in this extension study.

Treatment may continue for up to 3 years following the study last patient first visit, or until iptacopan becomes commercially available and/or reimbursed according to local post-trial access requirements, whichever occurs first.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

36

Fase

  • Fase 3

Acceso ampliado

Disponible fuera del ensayo clínico. Ver registro de acceso ampliado.

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

3 años a 20 años (Niño, Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

  • Signed informed consent by parent(s)/legal guardian(s) for the patient must be obtained before enrolling in the roll-over study and receiving study medication. A consent or assent may also be required for some patients depending upon their age and local requirements.
  • Male and female participant and has completed the treatment period in the Novartis sponsored pediatric study with iptacopan in any complement mediated disease (e.g., CLNP023I12201 or CLNP023G12301) on study drug.
  • Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
  • Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections should be up to date (i.e. any boosters required administered according to local regulations).
  • Per investigator's clinical judgement, the patient may benefit from continued treatment with iptacopan and has been clinically stable on iptacopan prior to enrollment in this extension study.

Exclusion Criteria:

  • Any comorbidity or medical condition (including but not limited to any active systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.
  • History of recurrent invasive infections caused by encapsulated organisms, such as Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus influenzae.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using effective methods of contraception during dosing of study treatment and for 1 week after stopping study treatment. Effective contraception methods include:
  • Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Note that periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of contraception.
  • Bilateral oophorectomy with or without hysterectomy, total hysterectomy, or bilateral salpingectomy at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment are they not considered to be of childbearing potential.
  • Bilateral tubal occlusion, bilateral tubal ligation (at least 6 weeks before taking study treatment).
  • Barrier methods of contraception: condom or occlusive cap (e.g., diaphragm or cervical/vault caps). For the UK: with spermicidal foam/gel/film/cream/vaginal suppository.
  • Use of hormonal contraception methods:
  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, intravaginal or transdermal.
  • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable.
  • Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).

Other protocol-defined inclusion/exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Iptacopan

Participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who continue to derive clinical benefit from treatment will receive open-label iptacopan. Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight-based dosing.

Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight-based dosing.

Otros nombres:
  • LNP023

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years

Number of participants with AEs, SAEs and major adverse vascular events (MAVE) including abnormal cardiovascular parameters, safety laboratory parameters and vital signs qualifying and reported as AEs.

From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of participants maintaining stable hemoglobin levels - PNH Indication only
Periodo de tiempo: From baseline through EOT/EOS, up to approximately 3 years

Proportion of participants with paroxysmal nocturnal hemoglobinuria (PNH) maintaining stable hemoglobin (Hb) levels in absence of red blood cell transfusions. Stable Hb is defined as no more than a ≥2 g/dL decrease from baseline.

From baseline through EOT/EOS, up to approximately 3 years
Proportion of participants maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL - PNH Indication only
Periodo de tiempo: Yearly through EOT/EOS, up to approximately 3 years

Proportion of participants with PNH maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL in the absence of red blood cell transfusions

Yearly through EOT/EOS, up to approximately 3 years
Proportion of participants with Hb levels ≥10 g/dL and ≥12 g/dL and LDH ≤1.5 ULN - PNH Indication only
Periodo de tiempo: From Day 1 through EOT/EOS, up to approximately 3 years

Proportion of participants with PNH achieving hemoglobin (Hb) levels ≥10 g/dL and ≥12 g/dL and lactate dehydrogenase (LDH) ≤1.5 times the upper limit of normal (ULN).

From Day 1 through EOT/EOS, up to approximately 3 years
Rate of Breakthrough Hemolysis - PNH Indication only
Periodo de tiempo: From baseline through End of Treatment/End of Study (up to approximately 3 years)

Breakthrough hemolysis events in participants with paroxysmal nocturnal hemoglobinuria (PNH). Clinical breakthrough hemolysis is defined based on protocol-specified clinical and laboratory criteria, including evidence of intravascular hemolysis and associated clinical signs/symptoms. The endpoint will be summarized as occurrences per year

From baseline through End of Treatment/End of Study (up to approximately 3 years)
Log-transformed ratio to baseline in Urinary Protein-to-Creatinine Ratio (UPCR) - IgAN indication only
Periodo de tiempo: Baseline and up to approximately 3 years

Log-transformed ratio to baseline in UPCR measured using first morning void (FMV) urine samples in participants with immunoglobulin A nephropathy (IgAN).

Baseline and up to approximately 3 years
Change from baseline in estimated Glomerular Filtration Rate (eGFR) - IgAN indication only
Periodo de tiempo: Baseline and up to approximately 3 years

Change from baseline in estimated glomerular filtration rate (eGFR) in participants with IgAN.

Baseline and up to approximately 3 years
Proportion of participants achieving UPCR <0.5 g/g - IgAN indication only
Periodo de tiempo: At EOT/EOS, up to approximately 3 years

Proportion of participants with IgAN achieving urinary protein-to-creatinine ratio (UPCR) <0.5 g/g.

At EOT/EOS, up to approximately 3 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

16 de noviembre de 2026

Finalización primaria (Estimado)

25 de noviembre de 2032

Finalización del estudio (Estimado)

25 de noviembre de 2032

Fechas de registro del estudio

Enviado por primera vez

11 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CLNP023I12001B
  • 2026-525677-39 (Número EudraCT)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .